Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fulgent Genetics ( (FLGT) ) just unveiled an announcement.
Fulgent Genetics reported fourth quarter and full-year 2025 results on February 27, 2026, with annual revenue rising 14% year-over-year to $322.7 million and fourth quarter revenue up 9% to $83.3 million. Despite GAAP losses of $23.4 million in the quarter and $60.5 million for the year, the company delivered non-GAAP income of $5.2 million in Q4 and $13.2 million for 2025, supported by margin improvements, AI and digital pathology-driven growth in its lab services business, and progress in its oncology pipeline, where FID-007 advanced through Phase 2 and FID-022 continued through Phase 1.
Management highlighted streamlined operations, enhanced efficiencies and a strong year-end liquidity position of $705.5 million in cash and investments, excluding an expected tax refund. Looking ahead to 2026, Fulgent guided to approximately $350 million in revenue and a non-GAAP loss per share, noting that the insourcing of work by its largest customer will be a headwind but may be partially or fully offset in the second half by contributions from the Bako and StrataDx acquisitions and ongoing strategic investments, leaving the company confident in its longer-term growth trajectory.
The most recent analyst rating on (FLGT) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.
Spark’s Take on FLGT Stock
According to Spark, TipRanks’ AI Analyst, FLGT is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and cash flow pressure), partially offset by a strong low-leverage balance sheet. Technicals are neutral-to-mildly supportive, while valuation is constrained by unprofitability and no dividend. The latest earnings call and recent strategic acquisitions improve the outlook via raised revenue/margin expectations and platform expansion, but they have not yet translated into strong GAAP profitability.
To see Spark’s full report on FLGT stock, click here.
More about Fulgent Genetics
Fulgent Genetics, Inc. is a technology-based precision medicine company with a well-established laboratory services business and a therapeutic development arm. Its lab division provides technical testing services and physician-led interpretation, while its therapeutics unit develops nanoencapsulated, targeted cancer drugs aimed at improving the safety and efficacy profiles of both new and existing oncology treatments as it transitions from diagnostics to a fully integrated precision medicine model.
Average Trading Volume: 203,709
Technical Sentiment Signal: Buy
Current Market Cap: $713.8M
Find detailed analytics on FLGT stock on TipRanks’ Stock Analysis page.